⌘K

Login Start Free

Home/Filings/4/0000943819-25-000187

4//SEC Filing

Farrell Michael J. 4

Accession 0000943819-25-000187

CIK 0000943819other

View on SEC.gov Company Profile

Filed

Dec 8, 7:00 PM ET

Accepted

Dec 9, 3:17 PM ET

Size

9.4 KB

Accession

0000943819-25-000187

Insider Transaction Report

Form 4

Period: 2025-12-08

Farrell Michael J.

DirectorChairman and CEO

Transactions

Exercise/Conversion
ResMed Common Stock
2025-12-08$146.34/sh+4,991$730,383→ 471,214 total
Sale
ResMed Common Stock
2025-12-08$251.41/sh−4,991$1,254,796→ 466,223 total
Exercise/Conversion
ResMed Common Stock Options
2025-12-08−4,991→ 54,903 total
Exercise: $146.34From: 2020-11-11Exp: 2026-11-21→ ResMed Common Stock (4,991 underlying)

Holdings

ResMed Common Stock
(indirect: By Trust)
2,090

Footnotes (3)

[F1]The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
[F2]This transaction was executed in multiple trades at prices ranging from $249.63 - $255.775. The price reported above reflects the weighted average sale price.
[F3]Represents date options first become exercisable. Options vest 1/3 per year.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

RESMED INC

CIK 0000943819

Entity typeother

Related Parties

1

filerCIK 0001485164

Filing Metadata

Form type: 4
Filed: Dec 8, 7:00 PM ET
Accepted: Dec 9, 3:17 PM ET
Size: 9.4 KB

View on SEC.gov